Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

Acquired bleeding disorders can accompany hematological, neoplastic, autoimmune,
cardiovascular or liver diseases, but can sometimes also arise spontaneously. They can …

Background Recombinant porcine factor VIII (rpFVIII, OBI‐1, susoctocog alfa) is used for the
treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA …

There is a dire need to develop an algorithm to improve the recognition of acquired
hemophilia A and B (AHA and AHB) in clinical practice. Initial and intensive care unit (ICU) …

Acquired hemophilia A (AHA) is a rare bleeding disorder in which acquired autoantibodies
to endogenous factor VIII (FVIII) decrease FVIII activity and lead to a bleeding phenotype. A …

Abstract Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder caused by
development of auto‐antibodies to endogenous coagulation factor VIII (FVIII). Recombinant …

One important limitation for achieving therapeutic expression of human factor VIII (FVIII) in
hemophilia A gene therapy is inefficient secretion of the FVIII protein. Substitution of five …

For several decades, therapeutic options for inherited deficiencies of factor VIII or IX
(hemophilia A or B, respectively) have largely been the replacement of the missing clotting …

Patients with acquired hemophilia A (AHA) often present in an emergency setting to
physicians not specialized in bleeding disorders.[1] If symptoms and laboratory signs are …

Background Measuring the activity of hemostatic agents used to treat hemophilia A often
requires drug-specific assays. In vitro assays show hemophilic clots have abnormal …